LEXPERT MAGAZINE
|
MAY 2018 25
|
CORPORATE TRANSACTIONS OF IMPORTANCE
|
MOUNTAIN PROVINCE
DIAMONDS INC. IN ITS
$325-MILLION OFFERING
AND $50-MILLION
REVOLVING CREDIT
CLOSING DATE: DECEMBER 14, 2017
On December 14, 2017, Mountain Province
Diamonds Inc. completed its $325-million
notes offering and $50-million revolving
credit agreement. e Notes were guaran-
teed by each of the company's subsidiaries
and were secured on a second-priority basis
by substantially all of the company's assets,
including the company's 49-per-cent partici-
pating interest in the joint venture related to
the Gahcho Kué diamond mine.
Bennett Jones LLP represented Moun-
tain Province Diamonds Inc. with a team
including Sander Grieve, Linda Misetich
Dann, Conrad Druzeta, Simon Grant, Brit-
tany Sargent and Matthew Vaughan.
Paul, Weiss, Riind, Wharton & Gar-
rison LLP was US counsel to Mountain
Province Diamonds Inc. with a team includ-
ing Adam Givertz, Stephen Centa, Ronnie
Ollo and Jason Brisebois.
Shearman & Sterling LLP was US coun-
sel to the underwriters with a team including
Jason Lehner, Ana Aur, Joanna Enns and
Katya Bogdanov.
Stikeman Elliott LLP was Canadian
counsel to the underwriters with a team
including Ivan Grbesic, Craig Mitchell,
Meaghan Obee Tower, Anas Youssef, Kris-
tina Vranjkovic and Laura von Heynitz.
Norton Rose Fulbright Canada LLP
was counsel to the security agent and lend-
ers for the revolving credit facility agreement
with a team including Geoffrey Gilbert, Ali-
son Babbitt and Edward Anido.
ARBUTUS CLOSES SECOND
TRANCHE OF A $116M
STRATEGIC INVESTMENT
FROM ROIVANT SCIENCES
CLOSING DATE: JANUARY 12, 2018
On January 12, 2018, Arbutus Biopharma
Corp. (Arbutus) closed on a transaction in-
volving the issue and sale of 664,000 series
A participating convertible preferred shares
of Arbutus (Preferred Shares) to Roivant Sci-
ences Ltd. (Roivant) for gross proceeds to Ar-
butus of US$66.4 million (Tranche 2).
Arbutus is a publicly-traded biopharma-
ceutical company dedicated to discovering,
developing and commercializing a cure for
patients suffering from chronic hepatitis
B infection, a disease of the liver caused by
hepatitis B virus. e company is developing
a portfolio of drug candidates with comple-
mentary mechanisms of action.
e Tranche 2 closing represents the sec-
ond of two tranches of Preferred Shares is-
sued to Roivant; together with the previously
announced Tranche 1 closing on November
7, 2017, they comprise the previously an-
nounced US$116.4 million strategic invest-
ment by Roivant in Arbutus.
Lawson Lundell LLP acted as lead Cana-
dian counsel for Roivant with a team led by
Valerie Mann and Crispin Arthur (corporate
Monique practised at Fogler,
Rubinoff LLP.
OUR QUALITY STARTS WITH OUR PEOPLE
Now her job is to make you better at yours.
Practical Law Canada provides legal know-how that gives lawyers
a better starting point. Our expert team of lawyer-editors creates
and maintains thousands of up-to-date, practical resources across
all major practice areas. We go beyond primary law and traditional
legal research to give you the resources needed to practise more
effi ciently, improve client services, and add more value.
REQUEST A FREE TRIAL TODAY
1-844-717-4488 | thomsonreuters.ca/practicallawcanada
© 2018 Thomson Reuters Canada Limited
00250QW-91913-CE
